Aim: To examine the effect of education on compliance with VTE prophylaxis guidelines. Method: Undertake retrospective(Sept 2009)and prospective(Oct 2009) analysis of hospital records collected over two acute surgical receiving weeks assessing demographics, presenting complaint, VTE risk and prescribing accuracy. Results: In cohort one, 76patients were admitted to the unit. Fourty-six (60.5%) male and 30(39.5%) female (range16-92y,mean48y). Fifty-three patients were indicated for Enoxaparin. Of these, 16(30.2%) received the correct dose, 19(40.4%) received an incorrect dose and 18(38.3%) received no thromboprophylaxis. Of those receiving an incorrect dose, 1(5.3%) was too high and 18(94.7%) doses too low. In cohort two, 73patients were admitted, 34(46.6%) male and 39(53.4%) female (range16-98y,mean50). Forty-seven patients were indicated with 19(40.4%) received the correct dose of Enoxaparin, 10(21.3%) received an incorrect dose and 18(38.3%) received no thromboprophylaxis. Of the 10 receiving an incorrect dose, 1(10%) was too high and 9(90%) too low. Between the two cohorts, the accuracy of Enoxaparin prescribing improved from 30.2%to 40. 4%(p¼0.28). In all cases VTE risk assessment and reasons for lack of thromboprophylaxis were never documented. Conclusion: Despite education with junior doctors, compliance with SIGN guidelines remains poor thus further efforts are needed improve education.
Objective: To evaluate the outcome of endovascular treatments for isolated internal iliac artery aneurysms. Methods: A systematic review of the literature using public domain databases was undertaken. All studies reporting on treatments of isolated hypogastric artery aneurysms by endovascular means were considered. Experience from our institution was involved in the analysis. The primary outcome measures were technical success, perioperative, 30-day, and overall mortality/morbidity. Results: Data was extracted from 30 articles fulfilling the selection criteria, and the study cohort consisted of 55 patients having undergone treatment of 59 internal iliac artery aneurysms. Ten patients (18%) were treated on an urgent or emergency basis for a ruptured aneurysm. Technical success was achieved in 71% of the cases. The most common reason for technical failure was incomplete exclusion of the aneurysm sac. Thirty-day mortality occurred in one patient (2%). The 30-day morbidity rate was 20%, and was mostly associated with insufficiency of the pelvic circulation. One aneurysm-related death occurred during a mean follow up period of 13 months (range, 0.5-56 months). Open surgical intervention for aneurysm-related complications was required in 5 patients.
Conclusions: Endovascular treatment of isolated internal iliac artery aneurysms is an effective alternative option, with satisfactory early and mid-term results. Aims: In kidney transplant recipients not treated with induction therapy, pre-transplant serum CXCR3-binding chemokines CXCL9 and CXCL10 levels are associated with acute rejection (AR) and graft loss. Since induction therapy potentially alters cellular responses to CXCR3-binding chemokines post-transplantation, we have tested predictive values of pretransplant serum CXCL9 and CXCL10 levels for AR in patients receiving either Alemtuzumab or Basiliximab induction. Method: 64 kidney transplant recipients, 44 receiving Basiliximab and 20 receiving Alemtuzumab, were observed for one year post-transplantation. Results: 12 patients experienced AR. Pre-transplant serum was assayed for CXCL9 and CXCL10 levels by ELISA. Total leukocyte gene expression was determined using real-time RT-PCR. No significant difference between nonrejecting patients and patients with AR, in CXCL9 levels (296.4 AE452.9 vs. 150.1 AE88.4, P ¼ns) or CXCL10 levels (158.2 AE91.1 vs. 97.5 AE37.6, P ¼ns) was observed. Analysis of peripheral blood CXCR3 expression showed a profound reduction of CXCR3 mRNA levels in Alemtzumab-treated patients. Conclusion: This study shows that pre-transplant serum CXCL9 and CXCL10 levels fail to predict AR in kidney transplant recipients receiving Alemtuzumab or Basiliximab, likely due to depletion or inactivation of 
